329 related articles for article (PubMed ID: 29047342)
21. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
22. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
Shantsila E; Wolff A; Lip GY; Lane DA
Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
[TBL] [Abstract][Full Text] [Related]
23. Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(9):1-106. PubMed ID: 28744335
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
Tsivgoulis G; Spengos K; Zakopoulos N; Manios E; Peppes V; Vemmos K
Age Ageing; 2005 Jan; 34(1):35-40. PubMed ID: 15591481
[TBL] [Abstract][Full Text] [Related]
25. Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts.
Robson J; Dostal I; Mathur R; Sohanpal R; Hull S; Antoniou S; Maccallum P; Schilling R; Ayerbe L; Boomla K
Br J Gen Pract; 2014 May; 64(622):e275-81. PubMed ID: 24771841
[TBL] [Abstract][Full Text] [Related]
26. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
[TBL] [Abstract][Full Text] [Related]
27. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
Hughes M; Lip GY;
Thromb Haemost; 2008 Feb; 99(2):295-304. PubMed ID: 18278178
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
29. Clopidogrel hydrogen sulphate for atrial fibrillation.
Garg N; Rajpurohit N; Flaker G
Expert Opin Pharmacother; 2011 Aug; 12(11):1781-7. PubMed ID: 21663525
[TBL] [Abstract][Full Text] [Related]
30. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
31. Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Själander S; Själander A; Svensson PJ; Friberg L
Europace; 2014 May; 16(5):631-8. PubMed ID: 24158253
[TBL] [Abstract][Full Text] [Related]
32. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Valentine N; Van de Laar FA; van Driel ML
Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
[TBL] [Abstract][Full Text] [Related]
33. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
34. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
Algra A; de Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
Cochrane Database Syst Rev; 2001; (4):CD001342. PubMed ID: 11687110
[TBL] [Abstract][Full Text] [Related]
35. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
Alamneh EA; Chalmers L; Bereznicki LR
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
[TBL] [Abstract][Full Text] [Related]
36. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
Sindet-Pedersen C; Staerk L; Lamberts M; Gerds TA; Berger JS; Nissen Bonde A; Langtved Pallisgaard J; Hansen ML; Torp-Pedersen C; Gislason GH; Bjerring Olesen J
Heart; 2018 Jun; 104(11):912-920. PubMed ID: 29092916
[TBL] [Abstract][Full Text] [Related]
37. Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk.
Tomlin AM; Lloyd HS; Tilyard MW
Eur J Prev Cardiol; 2017 Feb; 24(3):311-319. PubMed ID: 27798365
[TBL] [Abstract][Full Text] [Related]
38. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
39. [Atrial fibrillation and stroke].
Aamodt AH; Sandset PM; Atar D; Tveit A; Russell D
Tidsskr Nor Laegeforen; 2013 Aug; 133(14):1453-7. PubMed ID: 23929293
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
